Titan Pharmaceuticals, Inc. Overview
Pro stress-test →Titan Pharmaceuticals develops therapeutics for chronic disease treatment using its proprietary ProNeura long-term drug delivery platform. The company primarily operates through its lead product Probuphine (buprenorphine implant), marketed internationally, though U.S. commercialization was discontinued in 2020 and assets were sold in 2023.
Strategic Profile
Pro stress-test →Following discontinuation of its primary commercial product in the U.S., Titan has pivoted to exploring strategic alternatives including potential mergers and business combinations. The company maintains its proprietary ProNeura implant technology platform with early-stage pipeline candidates, though the company experienced a significant business transformation with a merger completion in October 2025.
Competitive Landscape
Pro stress-test →Titan operates in the specialty pharmaceutical space focusing on opioid use disorder and chronic disease treatment. Primary competition comes from established opioid maintenance therapy providers and broader drug delivery platform companies. Market position is considerably weakened post-merger and asset divestiture.
Industry Context
Titan Pharmaceuticals, Inc. operates in Specialty Pharmaceuticals / Drug Delivery Systems.
Key facts
Founded: 1992 · Headquarters: South San Francisco, CA, United States · Employees: N/A · Revenue: N/A · Market cap: ~$3-5M